|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4908433A
(en)
|
1984-04-25 |
1990-03-13 |
Sloan-Kettering Institute For Cancer Research |
Uses of interleukin-2
|
|
JPS6147500A
(ja)
|
1984-08-15 |
1986-03-07 |
Res Dev Corp Of Japan |
キメラモノクロ−ナル抗体及びその製造法
|
|
EP0173494A3
(en)
|
1984-08-27 |
1987-11-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric receptors by dna splicing and expression
|
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
|
JPS61134325A
(ja)
|
1984-12-04 |
1986-06-21 |
Teijin Ltd |
ハイブリツド抗体遺伝子の発現方法
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
EP0262802A3
(en)
|
1986-09-01 |
1990-01-31 |
Takeda Chemical Industries, Ltd. |
Medicament for the treatment or improvement of rheumatoid arthritis or systemic lupus erythematosus
|
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
|
ATE243754T1
(de)
|
1987-05-21 |
2003-07-15 |
Micromet Ag |
Multifunktionelle proteine mit vorbestimmter zielsetzung
|
|
US5466447A
(en)
|
1988-06-29 |
1995-11-14 |
Amgen Inc. |
Method for treating psoriasis
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
EP0436597B1
(en)
|
1988-09-02 |
1997-04-02 |
Protein Engineering Corporation |
Generation and selection of recombinant varied binding proteins
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
GB8905669D0
(en)
|
1989-03-13 |
1989-04-26 |
Celltech Ltd |
Modified antibodies
|
|
WO1991000906A1
(en)
|
1989-07-12 |
1991-01-24 |
Genetics Institute, Inc. |
Chimeric and transgenic animals capable of producing human antibodies
|
|
EP1690934A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
EP0585287B1
(en)
|
1990-07-10 |
1999-10-13 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
ATE300615T1
(de)
|
1990-08-29 |
2005-08-15 |
Genpharm Int |
Transgene mäuse fähig zur produktion heterologer antikörper
|
|
ATE352612T1
(de)
|
1990-08-29 |
2007-02-15 |
Pharming Intellectual Pty Bv |
Homologe rekombination in säugetier-zellen
|
|
CA2405246A1
(en)
|
1990-12-03 |
1992-06-11 |
Genentech, Inc. |
Enrichment method for variant proteins with alterred binding properties
|
|
ATE241011T1
(de)
|
1991-02-27 |
2003-06-15 |
Micromet Ag |
Serin-reiche peptidlinker
|
|
US5525491A
(en)
|
1991-02-27 |
1996-06-11 |
Creative Biomolecules, Inc. |
Serine-rich peptide linkers
|
|
EP0575485A1
(en)
|
1991-03-01 |
1993-12-29 |
Dyax Corp. |
Process for the development of binding mini-proteins
|
|
DK0580737T3
(da)
|
1991-04-10 |
2004-11-01 |
Scripps Research Inst |
Heterodimere receptorbiblioteker ved anvendelse af phagemider
|
|
EP0519596B1
(en)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
A method for reducing the immunogenicity of antibody variable domains
|
|
DE4122599C2
(de)
|
1991-07-08 |
1993-11-11 |
Deutsches Krebsforsch |
Phagemid zum Screenen von Antikörpern
|
|
US5229109A
(en)
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
|
AU701578B2
(en)
|
1992-08-21 |
1999-02-04 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
|
AU8124694A
(en)
|
1993-10-29 |
1995-05-22 |
Affymax Technologies N.V. |
In vitro peptide and antibody display libraries
|
|
DZ2788A1
(fr)
|
1998-05-15 |
2003-12-01 |
Bayer Ag |
Agonistes et antagonistes selectifs à IL-2.
|
|
US7371371B2
(en)
|
2001-08-13 |
2008-05-13 |
University Of Southern California |
Interleukin-2 mutants with reduced toxicity
|
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
|
WO2005007121A2
(en)
|
2003-07-18 |
2005-01-27 |
Massachusetts Institute Of Technology |
Mutant interleukin-2(il-2) polypeptides
|
|
BRPI0508470A
(pt)
|
2004-03-05 |
2007-07-31 |
Chiron Corp |
sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos
|
|
CA2656700A1
(en)
|
2006-07-06 |
2008-01-10 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
|
|
WO2009061853A2
(en)
|
2007-11-05 |
2009-05-14 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (il-2) polypeptides
|
|
DE102008023820A1
(de)
*
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
|
|
US20110200534A1
(en)
|
2008-08-21 |
2011-08-18 |
Industry-Academic Cooperation Foundation, Yonsei U |
T1-T2 Dual Modal MRI Contrast Agents
|
|
KR100873651B1
(ko)
|
2008-08-21 |
2008-12-11 |
김광한 |
잔디 식재기
|
|
WO2010021527A2
(ko)
|
2008-08-22 |
2010-02-25 |
Jung Tae Woo |
영상에 포함된 객체를 색인하는 시스템 및 방법
|
|
KR101111286B1
(ko)
|
2008-08-22 |
2012-03-14 |
한국생산기술연구원 |
발포체, 이 발포체의 제조장치, 이 발포체를 이용한 발포금속의 제조방법 및 발포금속 제조장치
|
|
KR100996532B1
(ko)
|
2008-08-22 |
2010-11-24 |
주식회사 엠아이텍 |
탄소나노튜브 기반 바이오센서에서 링커와 스페이서를 이용한 민감도 증가 방법
|
|
WO2010021526A2
(en)
|
2008-08-22 |
2010-02-25 |
Lg Electronics Inc. |
A method for processing additional information related to an announced service or content in an nrt service and a broadcast receiver
|
|
CN103772268B
(zh)
|
2008-08-22 |
2017-01-04 |
株式会社Lg化学 |
用于有机电子器件的材料以及使用所述材料的有机电子器件
|
|
WO2010021520A2
(ko)
|
2008-08-22 |
2010-02-25 |
엘지전자 주식회사 |
동기 채널 전송 방법
|
|
MX2011007647A
(es)
|
2009-01-21 |
2011-09-01 |
Amgen Inc |
Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
|
|
IT1395574B1
(it)
|
2009-09-14 |
2012-10-16 |
Guala Dispensing Spa |
Dispositivo di erogazione
|
|
CN102462837B
(zh)
|
2010-11-19 |
2016-08-03 |
生物林格斯Ip有限公司 |
抗炎组合物
|
|
HUE029139T2
(hu)
|
2011-02-10 |
2017-02-28 |
Roche Glycart Ag |
Mutáns interleukin-2 polipeptidek
|
|
ES2811624T3
(es)
|
2011-03-11 |
2021-03-12 |
Hopitaux Paris Assist Publique |
Régimen de dosificación de IL-2 para tratar lupus eritematoso sistémico
|
|
KR102220006B1
(ko)
|
2011-03-11 |
2021-02-24 |
아시스땅스 퍼블리끄-오삐또 드 빠리 |
자가면역 - 관련 또는 염증성 장애를 치료하기 위한 저용량 ｉｌ２ 의 용도
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
US9844582B2
(en)
|
2012-05-22 |
2017-12-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
|
|
RS61391B1
(sr)
|
2012-06-08 |
2021-02-26 |
Alkermes Pharma Ireland Ltd |
Ligandi modifikovani primenom cirkularnog permutiranja kao agonisti i antagonisti
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
US9580486B2
(en)
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
|
KR102042246B1
(ko)
|
2014-02-06 |
2019-11-28 |
에프. 호프만-라 로슈 아게 |
인터류킨-2 융합 단백질 및 이의 용도
|
|
GB2538666A
(en)
|
2014-07-21 |
2016-11-23 |
Delinia Inc |
Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
|
|
WO2016025385A1
(en)
|
2014-08-11 |
2016-02-18 |
Delinia, Inc. |
Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
MY188430A
(en)
|
2015-04-10 |
2021-12-08 |
Amgen Inc |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
|
PH12017501856B1
(en)
|
2015-04-10 |
2022-08-10 |
Amgen Inc |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
|
RU2611685C2
(ru)
|
2015-07-20 |
2017-02-28 |
Илья Владимирович Духовлинов |
Гуманизированное моноклональное антитело, специфичное к синдекану-1
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
KR102687530B1
(ko)
|
2016-05-04 |
2024-07-25 |
암젠 인크 |
T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
|
|
SG11201900616UA
(en)
|
2016-08-02 |
2019-02-27 |
Visterra Inc |
Engineered polypeptides and uses thereof
|
|
US11077172B2
(en)
|
2016-11-08 |
2021-08-03 |
Delinia, Inc. |
IL-2 variants for the treatment of psoriasis
|
|
CN116970059A
(zh)
|
2016-12-22 |
2023-10-31 |
库尔生物制药有限公司 |
T细胞调节性多聚体多肽及其使用方法
|
|
EP3580230B1
(en)
|
2017-02-07 |
2026-04-22 |
Vib Vzw |
Immune-cell targeted bispecific chimeric proteins and uses thereof
|
|
JP2020521452A
(ja)
|
2017-05-24 |
2020-07-27 |
パンディオン・セラピューティクス・インコーポレイテッド |
標的化免疫寛容
|
|
US20210277085A1
(en)
|
2017-05-24 |
2021-09-09 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
WO2019112852A1
(en)
|
2017-12-06 |
2019-06-13 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
US20210017247A1
(en)
|
2017-07-03 |
2021-01-21 |
Torque Therapeutics, Inc. |
Fusion Molecules Targeting Immune Regulatory Cells and Uses Thereof
|
|
MX2020003783A
(es)
|
2017-10-02 |
2021-01-08 |
Visterra Inc |
Moleculas de anticuerpo de cd138 y sus usos.
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
EP3720470A4
(en)
|
2017-12-06 |
2021-09-15 |
Pandion Operations, Inc. |
IL-2 MUTEINS AND THEIR USES
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US11319355B2
(en)
|
2017-12-19 |
2022-05-03 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
|
MX2021000801A
(es)
|
2018-07-24 |
2021-04-12 |
BioNTech SE |
Agonistas de il2.
|
|
JP7576027B2
(ja)
*
|
2018-10-18 |
2024-10-30 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
誘電コポリマー材料
|
|
CA3147757A1
(en)
|
2019-07-26 |
2021-02-04 |
Visterra, Inc. |
Interleukin-2 agents and uses thereof
|
|
EP4255466A1
(en)
|
2020-12-04 |
2023-10-11 |
Visterra, Inc. |
Methods of using interleukin-2 agents
|
|
KR20230147072A
(ko)
|
2021-01-20 |
2023-10-20 |
비스테라, 인크. |
인터류킨-2 돌연변이체 및 이의 용도
|
|
WO2023102463A1
(en)
|
2021-12-01 |
2023-06-08 |
Visterra, Inc. |
Methods of using interleukin-2 agents
|
|
EP4475875A1
(en)
|
2022-02-11 |
2024-12-18 |
Visterra, Inc. |
Interleukin-2 muteins for the treatment of autoimmune diseases
|